GL-IL2-138 / Genetic Leap - LARVOL DELTA

Genetic Leap receives FDA IND clearance for first-in-class, oral natural IL-2 modulator (PRNewswire) - "Genetic Leap...announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for GL-IL2-138, the company's small-molecule modulator of natural interleukin-2 (IL-2)....The drug will now be tested in a randomized, double-blind, placebo-controlled phase 1 clinical trial to evaluate its tolerability, pharmacokinetics and pharmacodynamics in humans."

IND • New P1 trial • Alzheimer's Disease • Immunology • Oncology